Key result
A scalable perfusion process with temperature reduction to 32 °C resulted in a 79-fold increase in total virus yields of almost pure (99.8%) antiviral OP7 chimera defective interfering particles.
Why the study?
Initial OP7 chimera DIP production in shake flasks yielded relatively low total virus titers and imperfect purity (78.7%), prompting establishment of a scalable production process.
An optimized, scalable perfusion process at 32 °C significantly increases the yield and purity of antiviral OP7 chimera defective interfering particles.
Answers are grounded in this paper and cite their sources.
Optimizes scalable DIP production for preclinical antiviral research; leaves open in vivo efficacy and clinical translation.
Defective interfering particles (DIPs) of influenza A virus (IAV) are suggested for use as broad-spectrum antivirals. We discovered a new type of IAV DIP named “OP7” that carries point mutations in its genome segment (Seg) 7 instead of a deletion as in conventional DIPs (cDIPs). Recently, using genetic engineering tools, we generated “OP7 chimera DIPs” that carry point mutations in Seg 7 plus a deletion in Seg 1. Together with cDIPs, OP7 chimera DIPs were produced in shake flasks in the absence of infectious standard virus (STV), rendering UV inactivation unnecessary. However, only part of the virions harvested were OP7 chimera DIPs (78.7%) and total virus titers were relatively low. Here, we describe the establishment of an OP7 chimera DIP production process applicable for large-scale production. To increase total virus titers, we reduced temperature from 37 to 32 °C during virus replication. Production of almost pure OP7 chimera DIP preparations (99.7%) was achieved with a high titer of 3.24 log10(HAU/100 µL). This corresponded to an 11-fold increase relative to the initial process. Next, this process was transferred to a stirred tank bioreactor resulting in comparable yields. Moreover, DIP harvests purified and concentrated by steric exclusion chromatography displayed an increased interfering efficacy in vitro. Finally, a perfusion process with perfusion rate control was established, resulting in a 79-fold increase in total virus yields compared to the original batch process in shake flasks. Again, a very high purity of OP7 chimera DIPs was obtained. This process could thus be an excellent starting point for good manufacturing practice production of DIPs for use as antivirals. Key points • Scalable cell culture-based process for highly effective antiviral OP7 chimera DIPs • Production of almost pure OP7 chimera DIPs in the absence of infectious virus • Perfusion mode production and purification train results in very high titers
No takes yet. Share an insight, caveat, or question.
Pelz et al. (2024) studied Influenza A virus (IAV) infection (in vitro model). Perfusion mode production with temperature reduction to 32 °C vs. Original batch process in shake flasks at 37 °C was evaluated on Total virus yield and purity of OP7 chimera DIPs (79-fold increase). A scalable perfusion process with temperature reduction to 32 °C resulted in a 79-fold increase in total virus yields of almost pure (99.8%) antiviral OP7 chimera defective interfering particles.
Synapse has enriched 10 related papers. Consider them for comparative context: